Valitor
4 known investors
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
Founders & leadership
WJ
Wesley JacksonPresident, Chief Scientific Officer & Member of the Board
GD
Gregory D. KunstChief Executive Officer